Pre-earnings options volume in Immunovant is normal with puts leading calls 8:3. Implied volatility suggests the market is anticipating a move near 3.5%, or $1.26, after results are released. Median move over the past eight quarters is 3.1%.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMVT:
- Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
- The biotech stocks to own in 2024, according to Piper Sandler
- Immunovant price target raised to $52 from $47 at Stifel
- Immunovant price target raised to $51 from $49 at BofA
- Immunovant price target raised to $51 from $47 at H.C. Wainwright